| Literature DB >> 31519498 |
Stefanie N Meyer1, Claudio Scuoppo2, Sofija Vlasevska1, Elodie Bal1, Antony B Holmes1, Mara Holloman1, Laura Garcia-Ibanez1, Sarah Nataraj1, Romain Duval1, Thomas Vantrimpont1, Katia Basso2, Nigel Brooks3, Riccardo Dalla-Favera4, Laura Pasqualucci5.
Abstract
Inactivating mutations of the CREBBP and EP300 acetyltransferases are among the most common genetic alterations in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). Here, we examined the relationship between these two enzymes in germinal center (GC) B cells, the normal counterpart of FL and DLBCL, and in lymphomagenesis by using conditional GC-directed deletion mouse models targeting Crebbp or Ep300. We found that CREBBP and EP300 modulate common as well as distinct transcriptional programs implicated in separate anatomic and functional GC compartments. Consistently, deletion of Ep300 but not Crebbp impaired the fitness of GC B cells in vivo. Combined loss of Crebbp and Ep300 completely abrogated GC formation, suggesting that these proteins partially compensate for each other through common transcriptional targets. This synthetic lethal interaction was retained in CREBBP-mutant DLBCL cells and could be pharmacologically targeted with selective small molecule inhibitors of CREBBP and EP300 function. These data provide proof-of-principle for the clinical development of EP300-specific inhibitors in FL and DLBCL.Entities:
Keywords: CREBBP; EP300; acetyltransferase inhibitor; dark zone; diffuse large cell lymphoma; germinal center; light zone; synthetic lethality
Mesh:
Substances:
Year: 2019 PMID: 31519498 DOI: 10.1016/j.immuni.2019.08.006
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745